Seeking Alpha

More on Array BioPharma (ARRY): FQ4 beats on a 9% Y/Y jump in total revenue. Net losses were...

More on Array BioPharma (ARRY): FQ4 beats on a 9% Y/Y jump in total revenue. Net losses were pared significantly from the prior year period, as its top line was boosted by a jump in sales and its bottom line benefited from milestone payments from AMGN. Shares +6.6% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector